Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 654 across all filing types
Latest filing 2023-02-02 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end Report) for Vitrolife Group for the year 2022. It contains comprehensive financial data, including income statements, balance sheet metrics, segment analysis, and management commentary on performance for both the fourth quarter and the full year. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR) as it covers a specific fiscal period and provides detailed financial results. Q4 2022
2023-02-02 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FOURTH QUARTER AND FULL YEAR REPORT 2022' and contains comprehensive financial statements, including income statements, key figures, and a CEO commentary on performance. It is a substantive financial report covering a period shorter than a full fiscal year (the fourth quarter) and the full year, providing detailed financial analysis rather than just a summary or announcement. Therefore, it is classified as an Interim/Quarterly Report. Q4 2022
2023-02-02 English
Bronwyn Brophy utses till ny VD för Vitrolife AB (publ)
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the appointment of Bronwyn Brophy as the new CEO and the departure timeline of the current CEO. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The text explicitly details the succession plan and new appointments.
2023-02-01 Swedish
Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
Board/Management Information Classification · 99% confidence The document is explicitly titled "Press Release" and announces a significant management change: the appointment of a new CEO, Bronwyn Brophy, and details regarding the transition of the outgoing CEO and interim appointments. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A).
2023-02-01 English
Correction press release: Vitrolife´s CEO has purchased shares
Director's Dealing Classification · 99% confidence The document is a press release titled "Correction press release: Vitrolife´s CEO has purchased shares." It explicitly details a transaction where the CEO acquired shares and states that this transaction will be reported to the Swedish Financial Supervisory Authority. This content directly relates to personal share transactions by company directors and executives (insider trades). This matches the definition for Director's Dealing (DIRS). The document length is short (2468 chars), but it is the primary announcement of the transaction itself, not an announcement of a report, so DIRS is preferred over RPA/RNS.
2022-10-28 English
Vitrolife´s CEO has purchased shares
Director's Dealing Classification · 100% confidence The document is a press release announcing that the CEO of Vitrolife, Thomas Axelsson, has purchased 12,000 shares of the company. This is a classic disclosure of a personal share transaction by a company executive, which falls under the category of Director's Dealing.
2022-10-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.